268 related articles for article (PubMed ID: 26255741)
1. Impact of preventive therapy on the risk of breast cancer among women with benign breast disease.
Cuzick J; Sestak I; Thorat MA
Breast; 2015 Nov; 24 Suppl 2(Suppl 2):S51-5. PubMed ID: 26255741
[TBL] [Abstract][Full Text] [Related]
2. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.
Fowble B; Hanlon AL; Patchefsky A; Freedman G; Hoffman JP; Sigurdson ER; Goldstein LJ
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):105-15. PubMed ID: 9747827
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer risk reduction therapy: the low-hanging fruit.
Bevers TB
J Natl Compr Canc Netw; 2015 Apr; 13(4):376-8. PubMed ID: 25870373
[No Abstract] [Full Text] [Related]
4. A System-Level Approach to Improve the Uptake of Antiestrogen Preventive Therapy among Women with Atypical Hyperplasia and Lobular Cancer
Brewster AM; Thomas P; Brown P; Coyne R; Yan Y; Checka C; Middleton L; Do KA; Bevers T
Cancer Prev Res (Phila); 2018 May; 11(5):295-302. PubMed ID: 29618460
[No Abstract] [Full Text] [Related]
5. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis.
Hershman D; Sundararajan V; Jacobson JS; Heitjan DF; Neugut AI; Grann VR
J Clin Oncol; 2002 Jan; 20(1):9-16. PubMed ID: 11773148
[TBL] [Abstract][Full Text] [Related]
6. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB
JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144
[TBL] [Abstract][Full Text] [Related]
7. Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
Fabian CJ; Kimler BF
Ann N Y Acad Sci; 2001 Dec; 952():44-59. PubMed ID: 11795443
[TBL] [Abstract][Full Text] [Related]
8. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
9. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen's clinical applications: old and new.
Buzdar AU
Arch Fam Med; 2000; 9(9):906-12. PubMed ID: 11031399
[TBL] [Abstract][Full Text] [Related]
11. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
Vogel VG
Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
[TBL] [Abstract][Full Text] [Related]
13. The Breast Cancer Continuum: insights from the tamoxifen trials impact future drug development strategies.
Lewis JP
Ann N Y Acad Sci; 2001 Dec; 949():327-32. PubMed ID: 11795371
[TBL] [Abstract][Full Text] [Related]
14. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
Tchou J; Hou N; Rademaker A; Jordan VC; Morrow M
Cancer; 2004 May; 100(9):1800-6. PubMed ID: 15112259
[TBL] [Abstract][Full Text] [Related]
15. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM
Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889
[TBL] [Abstract][Full Text] [Related]
16. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Management of High-Risk Breast Lesions.
Thomas PS
J Natl Compr Canc Netw; 2018 Nov; 16(11):1391-1396. PubMed ID: 30442737
[TBL] [Abstract][Full Text] [Related]
18. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
Fisher B; Costantino JP; Wickerham DL; Redmond CK; Kavanah M; Cronin WM; Vogel V; Robidoux A; Dimitrov N; Atkins J; Daly M; Wieand S; Tan-Chiu E; Ford L; Wolmark N
J Natl Cancer Inst; 1998 Sep; 90(18):1371-88. PubMed ID: 9747868
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
Tobias JS
Ann Oncol; 2004 Dec; 15(12):1738-47. PubMed ID: 15550578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
